SMARCD1

Across TCGA pan-cancer cohorts, SMARCD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMARCD1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SMARCD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMARCD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where SMARCD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.612	0.823	.004	41	view →
LUAD	DFS	Median	II,III,IV	0.302	0.673	.009	13	view →
PDAC	OS	Quartile	II,III,IV	0.786	0.450	.008	9	view →
CCRCC	OS	Quartile	All	0.966	0.761	.002	8	view →
LSCC	OS	Quartile	All	0.914	0.675	.027	6	view →
OV	DFS	Median	All	0.861	1.000	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMARCD1–HNSC (OS)

Open the HNSC breakdown →